INO
INO
NASDAQ · Biotechnology

Inovio Pharmaceuticals Inc

$1.16
-0.05 (-4.13%)
As of Oct 3, 2:29 AM ET ·
Financial Highlights (FY 2026)
Revenue
148.3K
Net Income
-191,911,522
Gross Margin
60.1%
Profit Margin
-130,006.0%
Rev Growth
-81.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 60.1% 60.1% 61.2% 61.2%
Operating Margin -132,877.4% -119,589.8% -0.7% -0.8%
Profit Margin -130,006.0% -123,505.7% -0.8% -0.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 148.3K 800.3K 29.02M 30.84M
Gross Profit 89.2K 481.2K 17.76M 18.88M
Operating Income -197,057,228 -957,104,723 -216,172 -232,129
Net Income -191,911,522 -932,112,087 -227,719 -278,307
Gross Margin 60.1% 60.1% 61.2% 61.2%
Operating Margin -132,877.4% -119,589.8% -0.7% -0.8%
Profit Margin -130,006.0% -123,505.7% -0.8% -0.9%
Rev Growth -81.5% -81.5% +16.9% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 56.78M 51.84M
Total Equity — — 78.40M 79.95M
D/E Ratio — — 0.72 0.65
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -192,949,626 -989,218,266 -290,155 -260,150
Free Cash Flow — — -255,634 -361,408